Elena A. Utkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena A. Utkina has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Sergei N. Pokrovsky
Institute of Experimental Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
11 shared publications - Olga I. Afanasieva
Institute of Experimental Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
10 shared publications - Oksana A. Razova
Chazov National Medical Research Center of Cardiology
4 shared publications - Elena A. Klesareva
Chazov National Medical Research Center of Cardiology
3 shared publications - Marat V. Ezhov
A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology n.a. acad. E.I. Chazov, Ministry of Health of the Russian Federation, Moscow 121552, Russia
3 shared publications A. A. Selishcheva
Moscow State University, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by North-Eastern Federal University in Vestnik of North-Eastern Federal University. Medical Sciences
- Vol. 44 (3) , 28-35
Association between salivary alkaline phosphatase and inflammatory periodontal diseases among adolescents in the European North of Russia
The high prevalence of periodontal inflammatory diseases (PID) among adolescents underscores the need to develop simple, non-invasive methods for their timely detection. Oral fluid is considered a promising diagnostic substrate, enabling the assessment of various biomarkers, particularly alkaline phosphatase (ALP), which is involved in inflammatory and reparative processes in periodontal tissues. However, there is a paucity of studies analyzing the diagnostic significance of this enzyme. Objective. To investigate the association between salivary ALP levels and clinical signs of PID in individuals aged 15–17 years permanently residing in the European North of Russia. In a cross-sectional study, participants (n = 439) residing in the Nenets Autonomous Okrug (n = 171), the Komi Republic (n = 146), and Murmansk Oblast (n = 121) underwent a dental examination with recording of periodontal parameters (bleeding, dental deposits, presence of periodontitis) and provided mixed saliva samples for subsequent determination of ALP activity. Data analysis was performed using Poisson regression models; unadjusted and adjusted (for sex, age, and place of residence) relative risks were calculated, and linear trends were assessed across quartiles of ALP distribution. Results: а direct statistically significant association was observed between enzyme concentration and the number of sextants exhibiting bleeding in the multivariable regression model, p for trend = 0.037. No statistically significant association was found between ALP levels and the likelihood of detecting periodontitis (p for trend = 0.404) or dental calculus (p = 0.521). Our results suggest that elevated ALP levels in the oral fluid of adolescents are associated with a greater prevalence of gingival bleeding. This suggests that this parameter may serve as a potential indicator of the severity and extent of generalized inflammation in periodontal tissues, although it is not specific for a diagnosis of periodontitis. Further prospective studies are required to definitively establish the clinical and diagnostic utility of ALP and to justify its application in routine clinical practice.
- 30 September 2026
- Published by North-Eastern Federal University in Vestnik of North-Eastern Federal University. Medical Sciences
- Vol. 44 (3) , 28-35
Open AccessAssociation between salivary alkaline phosphatase and inflammatory periodontal diseases among adolescents in the European North of Russia
The high prevalence of periodontal inflammatory diseases (PID) among adolescents underscores the need to develop simple, non-invasive methods for their timely detection. Oral fluid is considered a promising diagnostic substrate, enabling the assessment of various biomarkers, particularly alkaline phosphatase (ALP), which is involved in inflammatory and reparative processes in periodontal tissues. However, there is a paucity of studies analyzing the diagnostic significance of this enzyme. Objective. To investigate the association between salivary ALP levels and clinical signs of PID in individuals aged 15–17 years permanently residing in the European North of Russia. In a cross-sectional study, participants (n = 439) residing in the Nenets Autonomous Okrug (n = 171), the Komi Republic (n = 146), and Murmansk Oblast (n = 121) underwent a dental examination with recording of periodontal parameters (bleeding, dental deposits, presence of periodontitis) and provided mixed saliva samples for subsequent determination of ALP activity. Data analysis was performed using Poisson regression models; unadjusted and adjusted (for sex, age, and place of residence) relative risks were calculated, and linear trends were assessed across quartiles of ALP distribution. Results: а direct statistically significant association was observed between enzyme concentration and the number of sextants exhibiting bleeding in the multivariable regression model, p for trend = 0.037. No statistically significant association was found between ALP levels and the likelihood of detecting periodontitis (p for trend = 0.404) or dental calculus (p = 0.521). Our results suggest that elevated ALP levels in the oral fluid of adolescents are associated with a greater prevalence of gingival bleeding. This suggests that this parameter may serve as a potential indicator of the severity and extent of generalized inflammation in periodontal tissues, although it is not specific for a diagnosis of periodontitis. Further prospective studies are required to definitively establish the clinical and diagnostic utility of ALP and to justify its application in routine clinical practice.
- Open Access
- 15 December 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (4) , 47-52
A Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma
Elevated levels of apoB-100 containing lipoproteins and markers of systemic inflammation are often observed in patients with cardiovascular diseases. The concentrations can be reduced by pharmacotherapy or extracorporeal treatment. The sorbent, which removes CRP and atherogenic lipoproteins, simultaneously reduces the bloodstream concentration of these components. The efficacy and selectivity of the designed sorbent were studied, desorption constants of CRP (Kd = 4.2 10-8 M) and LDL (Kd = 7.7 10-7 M) were distribution coefficients of CRP (Kc = 101) and Lp(a) (Kc = 38) were calculated, and the ability to bind large amounts of atherogenic lipoproteins (up to 32 mg of TC per mL of the sorbent gel) was demonstrated. Our sorbent can be recommended for performing complex removal of CRP and atherogenic lipoproteins from the blood plasma in patients with refractory hyperlipidemia and CVD that are accompanied by elevated levels of CRP.
- 15 December 2021
- Published by Acta Naturae Ltd in Acta Naturae
- Vol. 13 (4) , 47-52
Open AccessA Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma
Elevated levels of apoB-100 containing lipoproteins and markers of systemic inflammation are often observed in patients with cardiovascular diseases. The concentrations can be reduced by pharmacotherapy or extracorporeal treatment. The sorbent, which removes CRP and atherogenic lipoproteins, simultaneously reduces the bloodstream concentration of these components. The efficacy and selectivity of the designed sorbent were studied, desorption constants of CRP (Kd = 4.2 10-8 M) and LDL (Kd = 7.7 10-7 M) were distribution coefficients of CRP (Kc = 101) and Lp(a) (Kc = 38) were calculated, and the ability to bind large amounts of atherogenic lipoproteins (up to 32 mg of TC per mL of the sorbent gel) was demonstrated. Our sorbent can be recommended for performing complex removal of CRP and atherogenic lipoproteins from the blood plasma in patients with refractory hyperlipidemia and CVD that are accompanied by elevated levels of CRP.
- Open Access
- 16 July 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (6) , 4138
C-reactive protein: pathogenetic characteristics and possible therapeutic target
It is known that the key mediator of acute phase response and marker of inflammation is C-reactive protein (CRP), the study of the role of which in the development of not only cardiovascular, but also infectious diseases has acquired particular relevance at the present time. CRP can be involved in all stages of the atherosclerotic process, including activation of the complement system and vascular endothelial cells, thrombosis, lipid accumulation, and apoptosis.The review describes modern concepts of the structure, biological and pathophysiological properties of CRP, its value as a cardiovascular risk predictor, as well as existing methods for reducing its blood level.According to recent studies, cardiovascular patients who achieved lower CRP levels with drug therapy had better clinical prognosis, making CRP an attractive therapeutic target. Currently, a search is underway for approaches to correct CRP levels associated with both the development of novel drugs and therapeutic apheresis methods to remove CRP from blood plasma.
- 16 July 2021
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 26 (6) , 4138
Open AccessC-reactive protein: pathogenetic characteristics and possible therapeutic target
It is known that the key mediator of acute phase response and marker of inflammation is C-reactive protein (CRP), the study of the role of which in the development of not only cardiovascular, but also infectious diseases has acquired particular relevance at the present time. CRP can be involved in all stages of the atherosclerotic process, including activation of the complement system and vascular endothelial cells, thrombosis, lipid accumulation, and apoptosis.The review describes modern concepts of the structure, biological and pathophysiological properties of CRP, its value as a cardiovascular risk predictor, as well as existing methods for reducing its blood level.According to recent studies, cardiovascular patients who achieved lower CRP levels with drug therapy had better clinical prognosis, making CRP an attractive therapeutic target. Currently, a search is underway for approaches to correct CRP levels associated with both the development of novel drugs and therapeutic apheresis methods to remove CRP from blood plasma.
- Open Access
- 15 October 2020
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 7 (4) , 45
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
Background and aims: The aim of this study was to investigate the influence of a single injection of Evolocumab on the dynamics of Lp(a), fractions of apoB100-containing lipoproteins, PCSK9, and their complexes in healthy individuals with elevated Lp(a) levels. Methods: This open-label, 4-week clinical study involved 10 statin-naive volunteers with Lp(a) >30 mg/dL, LDL-C < 4.9 mmol/L, and a moderate risk of cardiovascular events. The concentrations of Lp(a), lipids, PCSK9, circulating immune complexes (CIC), and plasma complexes of PCSK9 with apoB100-containing lipoproteins (Lp(a)–PCSK9 and LDL–PCSK9) were measured before and each week after Evolocumab (MABs) administration. Results: After a single dose injection of 140 mg of MABs, the median concentration of PCSK9 in serum increased from 496 to 3944 ng/mL; however, the entire pool of circulating PCSK9 remained bound with MABs for 2–3 weeks. LDL-C level decreased significantly from 3.36 mmol/L to 2.27 mmol/L during the first two weeks after the injection. Lp(a) concentrations demonstrated multidirectional changes in different patients with the maximal decrease on the second week. There were no positive correlations between the changes in levels of Lp(a), LDL-C, and TC. The change in the amount of circulating complex of PCSK9–Lp(a) was significantly less than of PCSK9–apoB100 (−5% and −47% after 1 week, respectively). Conclusions: A single administration of monoclonal antibodies against PCSK9 (Evolocumab) in healthy individuals with hyperlipoproteinemia(a) resulted in a decrease of Lp(a) of 14%, a 5% decrease in PCSK9–Lp(a), a 36% reduction of LDL-C, a 47% decrease in PCSK9–apoB100 and a tenfold increase in total serum PCSK9 concentration.
- 15 October 2020
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 7 (4) , 45
Open AccessEffect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
Background and aims: The aim of this study was to investigate the influence of a single injection of Evolocumab on the dynamics of Lp(a), fractions of apoB100-containing lipoproteins, PCSK9, and their complexes in healthy individuals with elevated Lp(a) levels. Methods: This open-label, 4-week clinical study involved 10 statin-naive volunteers with Lp(a) >30 mg/dL, LDL-C < 4.9 mmol/L, and a moderate risk of cardiovascular events. The concentrations of Lp(a), lipids, PCSK9, circulating immune complexes (CIC), and plasma complexes of PCSK9 with apoB100-containing lipoproteins (Lp(a)–PCSK9 and LDL–PCSK9) were measured before and each week after Evolocumab (MABs) administration. Results: After a single dose injection of 140 mg of MABs, the median concentration of PCSK9 in serum increased from 496 to 3944 ng/mL; however, the entire pool of circulating PCSK9 remained bound with MABs for 2–3 weeks. LDL-C level decreased significantly from 3.36 mmol/L to 2.27 mmol/L during the first two weeks after the injection. Lp(a) concentrations demonstrated multidirectional changes in different patients with the maximal decrease on the second week. There were no positive correlations between the changes in levels of Lp(a), LDL-C, and TC. The change in the amount of circulating complex of PCSK9–Lp(a) was significantly less than of PCSK9–apoB100 (−5% and −47% after 1 week, respectively). Conclusions: A single administration of monoclonal antibodies against PCSK9 (Evolocumab) in healthy individuals with hyperlipoproteinemia(a) resulted in a decrease of Lp(a) of 14%, a 5% decrease in PCSK9–Lp(a), a 36% reduction of LDL-C, a 47% decrease in PCSK9–apoB100 and a tenfold increase in total serum PCSK9 concentration.
- Open Access
- 14 June 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 82-89
The heterogeneity of lipoproteins and their role in the development of cardiovascular diseases
Вторичные гиперлипидемии: этиология и патогенез
- 14 June 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 82-89
Open AccessThe heterogeneity of lipoproteins and their role in the development of cardiovascular diseases
Вторичные гиперлипидемии: этиология и патогенез
- 1 May 2019
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 167 (1) , 24-29
A Low-Molecular-Weight Phenotype of Apolipoprotein(a) as a Factor Provoking Accumulation of Cholesterol by THP-1 Monocyte-Like Cells
Increased concentration of lipoprotein(a) is a risk factor of coronary heart disease. lipoprotein(a) consists of LDL-like and highly polymorphic apolipoprotein(a). Here we studied the effect of lipoprotein(a)-containing sera with different apolipoprotein(a) phenotypes on lipid accumulation by THP-1 monocyte-like cells. Cholesterol concentration in lysates of THP-1 cells was significantly higher after their incubation with lipoprotein(a)-containing serum samples with low-molecular-weight phenotype of apolipoprotein(a) in comparison with samples with a high-molecular-weight apolipoprotein(a) phenotype irrespective of initial cholesterol level as well as serum concentrations of apoB-100, oxidized LDL, and circulating immune complexes. The presence of the most atherogenic small dense LDL subfractions in examined sera in addition to a low-molecular-weight apolipoprotein(a) phenotype resulted in significant elevation of cholesterol accumulation by THP-1 cells. The data obtained explain greater atherogenicity of lipoprotein(a) with low-molecular-weight apolipoprotein(a) phenotype.
- 1 May 2019
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 167 (1) , 24-29
A Low-Molecular-Weight Phenotype of Apolipoprotein(a) as a Factor Provoking Accumulation of Cholesterol by THP-1 Monocyte-Like Cells
Increased concentration of lipoprotein(a) is a risk factor of coronary heart disease. lipoprotein(a) consists of LDL-like and highly polymorphic apolipoprotein(a). Here we studied the effect of lipoprotein(a)-containing sera with different apolipoprotein(a) phenotypes on lipid accumulation by THP-1 monocyte-like cells. Cholesterol concentration in lysates of THP-1 cells was significantly higher after their incubation with lipoprotein(a)-containing serum samples with low-molecular-weight phenotype of apolipoprotein(a) in comparison with samples with a high-molecular-weight apolipoprotein(a) phenotype irrespective of initial cholesterol level as well as serum concentrations of apoB-100, oxidized LDL, and circulating immune complexes. The presence of the most atherogenic small dense LDL subfractions in examined sera in addition to a low-molecular-weight apolipoprotein(a) phenotype resulted in significant elevation of cholesterol accumulation by THP-1 cells. The data obtained explain greater atherogenicity of lipoprotein(a) with low-molecular-weight apolipoprotein(a) phenotype.
- Open Access
- 9 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 8,p. 13-20
RAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIDE(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS
Aim.To investigate on the relation of lipoproteide(a) (Lpa), subfractions of atherogenic lipoproteides and titers of specific autoantibodies (autoAb) with the presence and severity of carotid arteries (CA) lesion in statin-naïve patients with severe hypercholesterolemia.Materialandmethods.To the study, 133 statin-naïve patients included, age 18 to 75 y.o., with absent clinical signs of coronary heart disease, and with first time diagnosed severe hypercholesterolemia (total cholesterol >7,5 mM/L and/or low density lipoproteides cholesterol >4,9 mM/L) with ultrasound duplex scan data of CA. All patients underwent measurement of Lpa concentration, lipid profile, subfractional content of apoB-100-containing lipoproteides and autoAb titer against them.Results.According to the data from duplex CA scan, patients were selected to 2 groups: control group (n=76) with no CA atherosclerosis; main group — patients with CA stenosis >20% (n=57). The participants of main group were older than controls, with no other clinical or lipid profile differences. Titre of autoAb IgM specific for Lpa and its oxidized modifications was significantly lower in CA atherosclerosis comparing to controls. The grade of CA stenosis in severe hypercholesterolemia patients positively correlated with age (r=0,24, p=0,005) and negatively — with autoAb IgM to apoB100-containing lipoproteides (r=-0,28 and r=-0,26, pConclusion.In patients with severe hypercholesterolemia Lpa is an autoantigen, and IgM autoantibodies to Lpa play antiatherogenic role.
- 9 September 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 8,p. 13-20
Open AccessRAISED IgM AUTOANTIBODY TITER TO LIPOPROTEIDE(A) AS ANTIATHEROGENIC FACTOR IN SEVERE HYPERCHOLESTEROLEMIA PATIENTS
Aim.To investigate on the relation of lipoproteide(a) (Lpa), subfractions of atherogenic lipoproteides and titers of specific autoantibodies (autoAb) with the presence and severity of carotid arteries (CA) lesion in statin-naïve patients with severe hypercholesterolemia.Materialandmethods.To the study, 133 statin-naïve patients included, age 18 to 75 y.o., with absent clinical signs of coronary heart disease, and with first time diagnosed severe hypercholesterolemia (total cholesterol >7,5 mM/L and/or low density lipoproteides cholesterol >4,9 mM/L) with ultrasound duplex scan data of CA. All patients underwent measurement of Lpa concentration, lipid profile, subfractional content of apoB-100-containing lipoproteides and autoAb titer against them.Results.According to the data from duplex CA scan, patients were selected to 2 groups: control group (n=76) with no CA atherosclerosis; main group — patients with CA stenosis >20% (n=57). The participants of main group were older than controls, with no other clinical or lipid profile differences. Titre of autoAb IgM specific for Lpa and its oxidized modifications was significantly lower in CA atherosclerosis comparing to controls. The grade of CA stenosis in severe hypercholesterolemia patients positively correlated with age (r=0,24, p=0,005) and negatively — with autoAb IgM to apoB100-containing lipoproteides (r=-0,28 and r=-0,26, pConclusion.In patients with severe hypercholesterolemia Lpa is an autoantigen, and IgM autoantibodies to Lpa play antiatherogenic role.
- Open Access
- 1 January 2017
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 16 (4) , 45-49
SUBFRACTIONS OF ATHEROGENIC APOB-LIPOPROTEIDES IN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA
Цель. Изучить связь концентрации липопротеида(а) [Лп(а)], подфракций липопротеидов промежуточной (ЛПП) и низкой (ЛНП) плотности у пациентов с впервые выявленной тяжелой гиперхолестеринемией (ГХС) с вероятностью диагноза семейной ГХС (СГХС). Материал и методы. В исследование включены 114 пациентов с впервые выявленной тяжелой ГХС (холестерин ЛНП >4,9 ммоль/л), без диагноза ишемической болезни сердца и не получавших гиполипидемическую терапию. Для оценки вероятности диагноза СГХС использовали голландские критерии Dutch Lipid Clinics Network. Показатели липидного спектра определяли ферментативным методом; Лп(а) — методом иммуноферментного анализа; подфракции липопротеидов с помощью системы Липопринт® (Quantimetrix, США). Результаты. Все пациенты были разделены согласно голландским критериям на две группы: I — (n=86) с возможной СГХС (3-5 баллов) и II — (n=28) с определенной или вероятной СГХС (≥6 баллов). Пациенты II группы имели более высокие уровни атерогенных апоВ100-содержащих липопротеидов относительно пациентов I группы: Лп(а) — 25,6 [5,1; 80,8] и 16,0 [6,2; 33,6] мг/дл (р=0,199), мелких плотных подфракций ЛНП (мпЛНП) — 4,0 [2,0; 8,5] и 1,0 [0; 3,0] мг/дл (рЗаключение. У больных с определенным и вероятным диагнозом СГХС относительно остальных пациентов с тяжелой ГХС наблюдается повышенная концентрация наиболее атерогенных апоВ100-содержащих липопротеидов: Лп(а), ЛПП-С и мпЛНП, при этом содержание мпЛНП ≥2 мг/дл или ЛПП-С ≥30 мг/дл на фоне гиперлипопротеидемии(а) увеличивает вероятность верификации СГХС.
- 1 January 2017
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 16 (4) , 45-49
Open AccessSUBFRACTIONS OF ATHEROGENIC APOB-LIPOPROTEIDES IN PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA
Цель. Изучить связь концентрации липопротеида(а) [Лп(а)], подфракций липопротеидов промежуточной (ЛПП) и низкой (ЛНП) плотности у пациентов с впервые выявленной тяжелой гиперхолестеринемией (ГХС) с вероятностью диагноза семейной ГХС (СГХС). Материал и методы. В исследование включены 114 пациентов с впервые выявленной тяжелой ГХС (холестерин ЛНП >4,9 ммоль/л), без диагноза ишемической болезни сердца и не получавших гиполипидемическую терапию. Для оценки вероятности диагноза СГХС использовали голландские критерии Dutch Lipid Clinics Network. Показатели липидного спектра определяли ферментативным методом; Лп(а) — методом иммуноферментного анализа; подфракции липопротеидов с помощью системы Липопринт® (Quantimetrix, США). Результаты. Все пациенты были разделены согласно голландским критериям на две группы: I — (n=86) с возможной СГХС (3-5 баллов) и II — (n=28) с определенной или вероятной СГХС (≥6 баллов). Пациенты II группы имели более высокие уровни атерогенных апоВ100-содержащих липопротеидов относительно пациентов I группы: Лп(а) — 25,6 [5,1; 80,8] и 16,0 [6,2; 33,6] мг/дл (р=0,199), мелких плотных подфракций ЛНП (мпЛНП) — 4,0 [2,0; 8,5] и 1,0 [0; 3,0] мг/дл (рЗаключение. У больных с определенным и вероятным диагнозом СГХС относительно остальных пациентов с тяжелой ГХС наблюдается повышенная концентрация наиболее атерогенных апоВ100-содержащих липопротеидов: Лп(а), ЛПП-С и мпЛНП, при этом содержание мпЛНП ≥2 мг/дл или ЛПП-С ≥30 мг/дл на фоне гиперлипопротеидемии(а) увеличивает вероятность верификации СГХС.
- Open Access
- 1 January 2017
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 91-96
INFLUENCE OF NICOTINIC ACID ON SUBFRACTIONAL SPECTRUM OF LOW, INTERMEDIATE AND HIGH DENSITY LIPOPROTEINS IN PATIENTS WITH HYPERLIPOPROTEINEMIA(а)
ВЛИЯНИЕ НИКОТИНОВОЙ КИСЛОТЫ НА ПОДФРАКЦИОННЫЙ СПЕКТР ЛИПОПРОТЕИДОВ ПРОМЕЖУТОЧНОЙ, НИЗКОЙ И ВЫСОКОЙ ПЛОТНОСТИ У ПАЦИЕНТОВ С ГИПЕРЛИПОПРОТЕИДЕМИЕЙ(а)
- 1 January 2017
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 5,p. 91-96
Open AccessINFLUENCE OF NICOTINIC ACID ON SUBFRACTIONAL SPECTRUM OF LOW, INTERMEDIATE AND HIGH DENSITY LIPOPROTEINS IN PATIENTS WITH HYPERLIPOPROTEINEMIA(а)
ВЛИЯНИЕ НИКОТИНОВОЙ КИСЛОТЫ НА ПОДФРАКЦИОННЫЙ СПЕКТР ЛИПОПРОТЕИДОВ ПРОМЕЖУТОЧНОЙ, НИЗКОЙ И ВЫСОКОЙ ПЛОТНОСТИ У ПАЦИЕНТОВ С ГИПЕРЛИПОПРОТЕИДЕМИЕЙ(а)